Darmmikrobiom und funktionelle gastrointestinale Erkrankungen

Tack J, Talley NJ, Camilleri M et al (2006) Functional gastroduodenal disorders. Gastroenterology 130(5):1466–1479 (Epub 2006/05/09)

Layer P, Andresen V, Pehl C et al (2011) S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Z Gastroenterol 49(2):237–293

Keller J, Layer P (2008) Funktionelle Dyspepsie. In: Riemann JF, Fischbach W, Galle PR, Mössner A (Hrsg) Gastroenterologie Das Referenzwerk für Klinik und Praxis. Thieme, Stuttgart, S 1781–1790

Dai F, Liu Y, Shi H et al (2014) Association of genetic variants in GNbeta3 with functional dyspepsia: a meta-analysis. Dig Dis Sci 59(8):1823–1830 (Epub 2014/02/22)

Gwee KA (2010) Post-Infectious Irritable Bowel Syndrome, an Inflammation-Immunological Model with Relevance for Other IBS and Functional Dyspepsia. J Neurogastroenterol Motil 16(1):30–34 (Epub 2010/06/11)

Pike BL, Porter CK, Sorrell TJ, Riddle MS (2013) Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol 108(10):1558–1563 (quiz 64, Epub 2013/05/29)

Futagami S, Itoh T, Sakamoto C (2015) Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther 41(2):177–188 (Epub 2014/10/29)

Dai C, Jiang M (2012) The incidence and risk factors of post-infectious irritable bowel syndrome: a meta-analysis. Hepatogastroenterology 59(113):67–72 (Epub 2011/10/26)

Thabane M, Kottachchi DT, Marshall JK (2007) Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 26(4):535–544 (Epub 2007/07/31)

Halvorson HA, Schlett CD, Riddle MS (2006) Postinfectious irritable bowel syndrome – a meta-analysis. Am J Gastroenterol 101(8):1894–1899 (quiz 942, Epub 2006/08/25)

Barbara G, Stanghellini V, Berti-Ceroni C et al (2000) Role of antibiotic therapy on long-term germ excretion in faeces and digestive symptoms after Salmonella infection. Aliment Pharmacol Ther 14(9):1127–1131 (Epub 2000/09/06)

Spiller R, Garsed K (2009) Postinfectious irritable bowel syndrome. Gastroenterology 136(6):1979–1988 (Epub 2009/05/22)

Simren M, Barbara G, Flint HJ et al (2013) Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 62(1):159–176 (Epub 2012/06/26)

Longstreth GF, Hawkey CJ, Mayer EA et al (2001) Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 15(7):959–964 (Epub 2001/06/26)

Marshall JK, Thabane M, Borgaonkar MR, James C (2007) Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 5(4):457–460 (Epub 2007/02/10)

Porter CK, Gormley R, Tribble DR et al (2011) The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 106(1):130–138 (Epub 2010/09/23)

Fujita K, Kaku M, Yanagase Y et al (1990) Physicochemical characteristics and flora of diarrhoeal and recovery faeces in children with acute gastro-enteritis in Kenya. Ann Trop Paediatr 10(4):339–345 (Epub 1990/01/01)

Pimentel M, Chow EJ, Lin HC (2003) Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 98(2):412–419

Yu D, Cheeseman F, Vanner S (2011) Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 60(3):334–340 (Epub 2010/11/30)

Lombardo L, Foti M, Ruggia O, Chiecchio A (2010) Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 8(6):504–508 (Epub 2010/01/12)

Posserud I, Stotzer PO, Bjornsson ES et al (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56(6):802–808

Keller J, Franke A, Storr M et al (2005) Klinisch relevante Atemtests in der gastroenterologischen Diagnostik – Empfehlungen der Deutschen Gesellschaft für Neurogastroenterologie und Motilität sowie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen. Z Gastroenterol 43(9):1071–1090

Noor SO, Ridgway K, Scovell L et al (2010) Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota. BMC Gastroenterol 10:134 (Epub 2010/11/16)

Carroll IM, Ringel-Kulka T, Keku TO et al (2011) Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 301(5):G799–G807 (Epub 2011/07/09)

Ponnusamy K, Choi JN, Kim J et al (2011) Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 60(Pt 6):817–827 (Epub 2011/02/19)

Rajilic-Stojanovic M, Biagi E, Heilig HG et al (2011) Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141(5):1792–1801 (Epub 2011/08/09)

Jalanka-Tuovinen J, Salojarvi J, Salonen A et al (2014) Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 63(11):1737–1745 (Epub 2013/12/07)

Mayer EA, Savidge T, Shulman RJ (2014) Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 146(6):1500–1512 (Epub 2014/03/04)

Tillisch K, Labus J, Kilpatrick L et al (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144(7):1394–1401, 401 e1–4 (Epub 2013/03/12)

Halmos EP, Power VA, Shepherd SJ et al (2014) A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146(1):67–75 e5 (Epub 2013/10/01)

Halmos EP, Christophersen CT, Bird AR et al (2015) Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 64(1):93–100 (Epub 2014/07/14)

Pineton de Chambrun G, Neut C, Chau A et al (2014) A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis (Epub 2014/12/10)

Yoon JS, Sohn W, Lee OY et al (2014) Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 29(1):52–59 (Epub 2013/07/09)

Begtrup LM, Muckadell OB de, Kjeldsen J et al (2013) Long-term treatment with probiotics in primary care patients with irritable bowel syndrome – a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 48(10):1127–1135 (Epub 2013/08/21)

Charbonneau D, Gibb RD, Quigley EM (2013) Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 4(3):201–211 (Epub 2013/04/04)

Menees SB, Maneerattannaporn M, Kim HM, Chey WD (2012) The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 107(1):28–35 (quiz 6, Epub 2011/11/03)

DuPont HL, Jiang ZD, Okhuysen PC et al (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 142(10):805–812

Xu D, Gao J, Gillilland M III et al (2014) Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 146(2):484–496 e4 (Epub 2013/10/29)

Lee KN, Lee OY (2014) Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 20(27):8886–8897 (Epub 2014/08/02)